Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL486251 | 0.79 | MEN1 (0.38) | KDM4EHSD17B10 | |
| SCHEMBL27418706 | 0.78 | NLRP3 (0.40) | KDM4E | |
| SCHEMBL5487767 | 0.77 | — | — | |
| SCHEMBL5478680 | 0.77 | — | — | |
| SCHEMBL1176695 | 0.77 | — | — | |
| SCHEMBL1355880 | 0.76 | ESR1 (0.36) | KDM4EMAPK1 | |
| SCHEMBL2513199 | 0.75 | NR3C2 (0.44) | — | |
| SCHEMBL183537 | 0.74 | NR3C2 (0.30) | — | |
| SCHEMBL7429506 | 0.74 | — | — | |
| SCHEMBL28816158 | 0.74 | APLNR (0.31) | APLNRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348694-A1 | SHELF LIFE- AND TRANSPORT STABILIZERS FOR POLYMERIZABLE COMPOUNDS | BASF SE (DE) | 2023-11-02 | — | — | US | claimed |
| EP-1905774-B1 | Fused heterocyclic compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-20 | — | — | EP | claimed |
| EP-1928461-B1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-04 | — | — | EP | claimed |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | claimed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | claimed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | claimed |
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | claimed |
| US-20100130483-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2010-05-27 | — | — | US | claimed |
| US-20100016281-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-21 | — | — | US | claimed |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | US | claimed |
| WO-2007019083-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | WO | claimed |
| US-20070032481-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | claimed |
| US-20060148789-A1 | Novel diazabicyclic aryl derivatives | NEUROSEARCH A/S (DK) | 2006-07-06 | — | — | US | claimed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | claimed |
| EP-1599476-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2005-11-30 | — | — | EP | claimed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | claimed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | claimed |
| US-6884815-B1 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2005-04-26 | — | — | US | claimed |
| WO-2004076453-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2004-09-10 | — | — | WO | claimed |
| US-6316472-B1 | Heterosubstituted pyridine derivatives as PDE 4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2001-11-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130483-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | CHRNA6, CHRNA10, CHRNA2 | MAPK10 447/4885APLNR 432/4885KDM4E 1998/4885 |
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | MAPK10 3561/4885APLNR 2319/4885KDM4E 3290/4885 |
| US-20060148789-A1 | Novel diazabicyclic aryl derivatives | CHRNA6, CHRNA10, CHRNA2 | MAPK10 447/4885APLNR 432/4885KDM4E 1998/4885 |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | MAPK10 3561/4885APLNR 2319/4885KDM4E 3290/4885 |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | MAPK10 158/4885APLNR 4756/4885KDM4E 1954/4885 |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | MAPK10 3561/4885APLNR 2319/4885KDM4E 3290/4885 |
| US-20070032481-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR5A, HTR6 | MAPK10 3451/4885APLNR 1244/4885KDM4E 4046/4885 |
| US-20100190787-A1 | Modulators of Mitotic Kinases | CDK1, BUB1, BUB1B | MAPK10 165/4885APLNR 4788/4885KDM4E 2817/4885 |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | MAPK10 158/4885APLNR 4756/4885KDM4E 1954/4885 |
| US-20100016281-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR5A, HTR6 | MAPK10 3451/4885APLNR 1244/4885KDM4E 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.